The World Health Organization (WHO), the Joint Expert Committee on Food Additives (JECFA), and the International Agency for Research on Cancer (IARC) have all released assessments of the non-sugar sweetener aspartame's effects on human health today. IARC classified aspartame as probably carcinogenic to humans (IARC Group 2B) due to "limited evidence" for its carcinogenicity in humans, while JECFA reiterated the recommended daily consumption of 40 mg/kg body weight.
Since the 1980s, diet drinks, chewing gum, gelatin, ice
cream, dairy goods including yogurt and morning cereal, toothpaste, and
pharmaceuticals like cough drops and chewable vitamins have all employed
aspartame, an artificial (chemical) sweetener.
"One of the biggest causes of death worldwide is
cancer. Cancer claims the lives of 1 in 6 people each year. In an effort to
lower these figures and the human toll, science is constantly developing to
evaluate potential beginning or facilitating factors of cancer, according to
Dr. Francesco Branca, Director of the Department of Nutrition and Food Safety,
WHO. "While safety is not a major concern at the doses that are commonly
used," the assessments of aspartame have shown, "potential effects
have been described that need to be investigated by more and better
studies."
To evaluate the potential carcinogenic risk and other health
hazards connected with aspartame intake, the two organizations carried out
separate but complementary reviews. IARC had never assessed aspartame before,
although JECFA has done so three times.
Both analyses recognized gaps in the evidence for cancer
(and other health impacts) after reading the pertinent scientific literature.
A kind of liver cancer called hepatocellular carcinoma, for
which there is particular evidence, led the IARC to classify aspartame as
probably carcinogenic to humans (Group 2B). Additionally, there was scant
evidence of cancer in research animals and scant information regarding
potential cancer-causing pathways.
JECFA came to the conclusion that there was insufficient
evidence to justify changing the previously defined recommended daily intake
(ADI) for aspartame, which is 0 to 40 mg/kg body weight. Therefore, the
committee reiterated that it is safe for a person to ingest up to this daily
limit. For instance, an adult weighing 70 kg would need to consume more than
9–14 cans of diet soft drinks per day, assuming no further intake from other
food sources, to go above the permissible daily intake.
By identifying an agent's particular characteristics and
potential for harm, such as cancer, the IARC's hazard identifications are the
first important step in understanding the carcinogenicity of an agent. The
strength of the scientific evidence supporting a substance's ability to cause human
cancer is reflected in IARC classifications, but not the likelihood that a
person would get cancer at a certain exposure level. All exposure categories
(such as food and occupational) are taken into account during the IARC hazard
evaluation. The third highest level of the four categories of the
strength-of-evidence classification, Group 2B, is typically employed when there
is either weak but not conclusive evidence for cancer in humans or strong but
not both conclusive evidence for cancer in experimental animals.
Dr. Mary Schubauer-Berigan of the IARC Monographs program
said, "The findings of limited evidence of carcinogenicity in humans and
animals, and of limited mechanistic evidence on how carcinogenicity may occur,
underscore the need for more research to clarify whether consumption of
aspartame poses a carcinogenic hazard."
JECFA's risk assessments establish the likelihood that a
certain form of harm, such as cancer, may manifest under particular
circumstances and exposure levels. JECFA frequently considers IARC categories
while making decisions.
According to Dr. Moez Sanaa, WHO's Head of the Standards and
Scientific Advice on Food and Nutrition Unit, "JECFA also considered the
evidence on cancer risk, in animal and human studies, and concluded that the
evidence of an association between aspartame consumption and cancer in humans
is not convincing." "In the present cohorts, we need better research
with longer follow-up and repeated dietary questionnaires. Randomized
controlled trials are required, as well as investigations into the molecular
processes involved in the regulation of insulin, metabolic syndrome, and
diabetes, particularly in relation to carcinogenicity.
Based on scientific data gathered from a variety of sources,
including peer-reviewed papers, government reports, and studies carried out for
regulatory purposes, the IARC and JECFA evaluated the effects of aspartame.
Both committees have taken procedures to assure the independence and
trustworthiness of their assessments, which have been verified by independent
experts who have evaluated the studies.
IARC and WHO will continue to keep an eye on new information
and support independent research teams in their efforts to do more studies on the
potential link between aspartame exposure and consumer health impacts.
Reference: WHO

